These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29729815)

  • 61. Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].
    Tsimafeyeu I; Ludes-Meyers J; Stepanova E; Daeyaert F; Khochenkov D; Joose JB; Solomko E; Van Akene K; Peretolchina N; Yin W; Ryabaya O; Byakhov M; Tjulandin S
    Eur J Cancer; 2017 Jan; 70():156. PubMed ID: 27919550
    [No Abstract]   [Full Text] [Related]  

  • 62. Corrigendum to "The role of sodium intake in nephrolithiasis: Epidemiology, pathogenesis, and future directions" [Eur J Intern Med 35 (2016) 16-19].
    Afsar B; Kiremit MC; Sag AA; Tarim K; Acar O; Esen T; Solak Y; Covic A; Kanbay M
    Eur J Intern Med; 2017 Jan; 37():90. PubMed ID: 27899242
    [No Abstract]   [Full Text] [Related]  

  • 63. Corrigendum to "Restoration of sirt1 function by pterostilbene attenuates hypoxia-reoxygenation injury in cardiomyocytes" [Eur. J. Pharmacol. 776 (2016) 26-33].
    Guo Y; Zhang L; Li F; Hu CP; Zhang Z
    Eur J Pharmacol; 2016 Jul; 782():120. PubMed ID: 27180043
    [No Abstract]   [Full Text] [Related]  

  • 64. Corrigendum to "Dissociative sensibility disorders - A retrospective case series and systematic literature review" [Eur J Paediatr Neurol (2018) 27-38].
    Weber P; Erlacher R
    Eur J Paediatr Neurol; 2018 May; 22(3):573. PubMed ID: 29548596
    [No Abstract]   [Full Text] [Related]  

  • 65. Corrigendum to "Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity" [Eur. J. Med. Chem. 55 (2012) 220-227].
    Chen KF; Tai WT; Hsu CY; Huang JW; Liu CY; Chen PJ; Kim I; Shiau CW
    Eur J Med Chem; 2018 Jan; 143():2015. PubMed ID: 29113744
    [No Abstract]   [Full Text] [Related]  

  • 66. Corrigendum to "6-Amino-2,4,5-trimethylpyridin-3-ols: A new general synthetic route and antiangiogenic activity" [Eur. J. Med. Chem. 74 (2014) 126-139].
    Kim DG; Kang Y; Lee H; Lee EK; Nam TG; Kim JA; Jeong BS
    Eur J Med Chem; 2017 Dec; 141():734-735. PubMed ID: 28988929
    [No Abstract]   [Full Text] [Related]  

  • 67. Corrigendum to 'Clinical picture and risk prediction of short-term mortality in cardiogenic shock' [Eur J Heart Fail] 2015 May;17(5):501-9. doi: 10.1002/ejhf.260.
    Eur J Heart Fail; 2015 Sep; 17(9):984. PubMed ID: 26377116
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].
    Eggink FA; Mom CH; Bouwman K; Boll D; Becker JH; Creutzberg CL; Niemeijer GC; van Driel WJ; Reyners AK; van der Zee AG; Bremer GL; Ezendam NP; Kruitwagen RF; Pijnenborg JM; Hollema H; Nijman HW; van der Aa MA
    Eur J Cancer; 2017 Oct; 84():370. PubMed ID: 28844347
    [No Abstract]   [Full Text] [Related]  

  • 69. Corrigendum to "Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer" [Eur J Cancer 40 (18) (2004) 2717-2725].
    Martin TA; Watkins G; Mansel RE; Jiang WG
    Eur J Cancer; 2018 Jan; 88():115-116. PubMed ID: 29174182
    [No Abstract]   [Full Text] [Related]  

  • 70. Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].
    du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S
    Eur J Cancer; 2016 Sep; 65():192-193. PubMed ID: 27468640
    [No Abstract]   [Full Text] [Related]  

  • 71. Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64].
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Castillo-Tong DC; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jun; 60():226. PubMed ID: 27106403
    [No Abstract]   [Full Text] [Related]  

  • 72. Corrigendum to 'Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential'[Eur J Heart Fail 2015; 17:764-771].
    Eur J Heart Fail; 2015 Sep; 17(9):985. PubMed ID: 26377117
    [No Abstract]   [Full Text] [Related]  

  • 73. Corrigendum to: "Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice": [Eur.J.Pharmacol.670(2011)441-447].
    Tsai SJ; Chao CY; Yin MC
    Eur J Pharmacol; 2018 Jan; 819():293. PubMed ID: 29325911
    [No Abstract]   [Full Text] [Related]  

  • 74. Corrigendum to "Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy" [Eur J Cancer 75 (April 2017) 109-116].
    Puliti D; Bucchi L; Mancini S; Paci E; Baracco S; Campari C; Canuti D; Cirilli C; Collina N; Conti GM; Di Felice E; Falcini F; Michiara M; Negri R; Ravaioli A; Sassoli De' Bianchi P; Serafini M; Zorzi M; Caldarella A; Cataliotti L; Zappa M;
    Eur J Cancer; 2017 Nov; 85():160. PubMed ID: 28870467
    [No Abstract]   [Full Text] [Related]  

  • 75. Corrigendum to "EEG changes in rolandic epilepsy under treatment with Levetiracetam and Sulthiame" [Eur J Paediatr Neurol 21 (Suppl. 1) (June 2017) e97].
    Tacke M; Borggraefe I; Gerstl L; Heinen F; Vill K; Bonfert M; Bast T
    Eur J Paediatr Neurol; 2017 Nov; 21(6):e1. PubMed ID: 28797736
    [No Abstract]   [Full Text] [Related]  

  • 76. Corrigendum to "Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles" [Eur J Cancer 70 (2017) 62-74].
    Read J; Ingram A; Al Saleh HA; Platko K; Gabriel K; Kapoor A; Pinthus J; Majeed F; Qureshi T; Al-Nedawi K
    Eur J Cancer; 2017 Sep; 83():335. PubMed ID: 28764945
    [No Abstract]   [Full Text] [Related]  

  • 77. 'Corrigendum to "Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins" [Eur J Cancer 81 (August 2017) 203-205]'.
    Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
    Eur J Cancer; 2017 Dec; 87():221. PubMed ID: 28986136
    [No Abstract]   [Full Text] [Related]  

  • 78. Corrigendum to: The Italian study on the Mitroflow postoperative results (ISTHMUS): a 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis [Eur J Cardiothorac Surg 2011;39:18-26].
    ISTHMUS Investigators
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):806. PubMed ID: 28329233
    [No Abstract]   [Full Text] [Related]  

  • 79. Corrigendum to "Software tools of the Computis European project to process mass spectrometry images an experimental and theoretical study" [Eur. J. Mass Spectrom. 20(5), 351-360 (2014)].
    Robbe MF; Both JP; Prideaux B; Klinkert I; Picaud V; Schramm T; Hester A; Guevara V; Stoeckli M; Roempp A; Heeren RM; Spengler B; Gal O; Haan S
    Eur J Mass Spectrom (Chichester); 2014; 20(6):487. PubMed ID: 25905873
    [No Abstract]   [Full Text] [Related]  

  • 80. Corrigendum to "Andrographolide-loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell line" [Eur. J. Pharm. Biopharm. 119 (2017) 253-263].
    Guccione C; Oufir M; Piazzini V; Eigenmann DE; Jähne EA; Zabela V; Faleschini MT; Bergonzi MC; Smiesko M; Hamburger M; Bilia AR
    Eur J Pharm Biopharm; 2017 Nov; 120():146. PubMed ID: 28941379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.